68Ga-FAPI PET/CT 用于细胞减灭术前后腹膜癌评估
本病例来自前瞻性研究 NCT04416165,55 岁女性胰腺肿物患者同时接受 18F-FDG 与 68Ga-FAPI PET/CT 评估。68Ga-FAPI PET/CT 在肠系膜和大网膜显示比 18F-FDG 更多的异常摄取灶,疑为胰腺癌转移;细胞减灭术后病理确诊胰腺腺泡细胞癌,术后 3 个月随访 68Ga-FAPI PET/CT 示全腹部 68Ga-FAPI 活性减低,反应良好。
要点
- 68Ga-FAPI PET/CT 较 18F-FDG 显示更多肠系膜和大网膜异常摄取灶。
- 术后病理确诊为胰腺腺泡细胞癌。
- 术后 3 个月 68Ga-FAPI PET/CT 示全腹部活性减低,反应良好。
核心结论
- 68Ga-FAPI PET/CT 在腹膜癌评估中可显示比 18F-FDG 更多的异常摄取灶,并可用于术后随访评估治疗反应。
研究设计与样本
- 前瞻性研究 NCT04416165 中的一例 55 岁女性病例。
主要发现
- 18F-FDG 和 68Ga-FAPI PET/CT 均显示胰腺肿物伴示踪剂摄取增高。
- 68Ga-FAPI PET/CT 在肠系膜和大网膜显示比 18F-FDG 更多的异常摄取灶,疑为胰腺癌转移。
- 细胞减灭术后病理确诊为胰腺腺泡细胞癌。
- 术后 3 个月随访 68Ga-FAPI PET/CT 显示全腹部 68Ga-FAPI 活性减低,反应良好。
临床怎么用
- 对疑诊腹膜癌的胰腺肿瘤患者,可考虑 68Ga-FAPI PET/CT 辅助评估腹膜播散范围。
- 术后可用 68Ga-FAPI PET/CT 随访评估治疗反应。
局限性
- 本文为单例病例报告,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 55-year-old woman underwent 18F-FDG and 68Ga-FAPI PET/CT for tumor detection and staging under the prospective study NCT04416165. Both scans showed a mass lesion with increased tracer uptake in the pancreas. Moreover, 68Ga-FAPI PET/CT showed a greater number of abnormal foci in the mesentery and omentum than that shown with 18F-FDG. These abnormal foci were suspected to be metastases from pancreatic cancer. The patient subsequently underwent a cytoreductive surgery, and postoperative histopathology confirmed the diagnosis of acinar cell carcinoma of pancreas. Follow-up 68Ga-FAPI PET/CT (3 months after surgery) showed an excellent response with decreasing 68Ga-FAPI activity in the whole abdomen.
引用
- Zhao L, Pang Y, Wei J, et al. Use of 68Ga-FAPI PET/CT for Evaluation of Peritoneal Carcinomatosis Before and After Cytoreductive Surgery. Clin Nucl Med. 2021. PMID: 33782310. doi:10.1097/RLU.0000000000003611
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。